Gilead’s Remdesivir Wins FDA’s First COVID-19 Drug Approval

The FDA approval does not extend to children under age 12 who are hospitalized with COVID-19 and who weigh between 3.5 kg (7.7 pounds) and 40 kg (88 pounds) because clinical trials in that subpopulation of patients remain ongoing.

The post Gilead’s Remdesivir Wins FDA’s First COVID-19 Drug Approval appeared first on GEN – Genetic Engineering and Biotechnology News.

Published on Fri, 23 Oct 2020 12:30:58 +0000 on behalf of power automate collection ends with item